Fund Holdings — Sarissa Capital Management LP

Total Portfolio Value:
$402.33M
Total Bought:
$2.85M
Total Sold:
$162.30M
Net Transaction:
-$159.44M
Securities
▲▼
SharesValue
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Innoviva, Inc.(INVA)7,277,0007,277,0000$119.34M$140.52M34.93%+$21.18M
Ironwood Pharmaceuticals, Inc.CL A(IRWD)16,390,00016,390,0000$106.86M$67.53M16.78%-$39.34M
Gilead Sciences, Inc.(GILD)1,103,282763,333-339,949$75.70M$64.00M15.91%-$11.70M
Cytokinetics, Incorporated(CYTK)1,110,0001,110,0000$60.14M$58.61M14.57%-$1.53M
Neurocrine Biosciences, Inc.(NBIX)410,483410,4830$56.51M$47.30M11.76%-$9.22M
Amarin Corp PlcADR24,850,62324,850,6230$17.10M$15.58M3.87%-$1.52M
Biogen Inc.(BIIB)643,00026,950-616,050$149.06M$5.22M1.30%-$143.84M
Lantheus Holdings, Inc.(LNTH)026,000+26,000$0$2.85M0.71%+$2.85M
Vor Biopharma Inc.(VOR)618,000618,0000$618.0K$432.6K0.11%-$185.4K
Regulus Therapeutics Inc185,183185,1830$330.6K$290.7K0.07%-$39.8K
BioCryst Pharmaceuticals, Inc.(BCRX)1,094,1680-1,094,168$6.76M$0—-$6.76M
Page 1 of 1